193 related articles for article (PubMed ID: 15032090)
1. [The autoimmune lymphoproliferative syndrome: a disorder of programmed cell death].
Seegers D; Peña AS; Bouma G
Ned Tijdschr Geneeskd; 2004 Feb; 148(8):371-6. PubMed ID: 15032090
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis.
Kanegane H; Vilela MM; Wang Y; Futatani T; Matsukura H; Miyawaki T
Pediatr Nephrol; 2003 May; 18(5):454-6. PubMed ID: 12736807
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.
Jackson CE; Fischer RE; Hsu AP; Anderson SM; Choi Y; Wang J; Dale JK; Fleisher TA; Middelton LA; Sneller MC; Lenardo MJ; Straus SE; Puck JM
Am J Hum Genet; 1999 Apr; 64(4):1002-14. PubMed ID: 10090885
[TBL] [Abstract][Full Text] [Related]
4. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome.
Straus SE; Sneller M; Lenardo MJ; Puck JM; Strober W
Ann Intern Med; 1999 Apr; 130(7):591-601. PubMed ID: 10189330
[TBL] [Abstract][Full Text] [Related]
5. ALPS: an autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Puck JM; Sneller MC
Semin Immunol; 1997 Feb; 9(1):77-84. PubMed ID: 9106310
[TBL] [Abstract][Full Text] [Related]
6. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype.
Worth A; Thrasher AJ; Gaspar HB
Br J Haematol; 2006 Apr; 133(2):124-40. PubMed ID: 16611303
[TBL] [Abstract][Full Text] [Related]
8. Residual CD95-pathway function in children with autoimmune lymphoproliferative syndrome is independent from clinical state and genotype of CD95 mutation.
Fuchs H; Posovszky C; Lahr G; van der Werff ten Bosch J; Boehler T; Debatin KM
Pediatr Res; 2009 Feb; 65(2):163-8. PubMed ID: 18948840
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a new germline Fas gene mutation.
Del-Rey MJ; Manzanares J; Bosque A; Aguiló JI; Gómez-Rial J; Roldan E; Serrano A; Anel A; Paz-Artal E; Allende LM
Immunobiology; 2007; 212(2):73-83. PubMed ID: 17336828
[TBL] [Abstract][Full Text] [Related]
10. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
[TBL] [Abstract][Full Text] [Related]
11. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model.
Nagata S
J Hum Genet; 1998; 43(1):2-8. PubMed ID: 9609991
[TBL] [Abstract][Full Text] [Related]
12. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
[TBL] [Abstract][Full Text] [Related]
13. HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia).
Vacek MM; Schäffer AA; Davis J; Fischer RE; Dale JK; Adams S; Straus SE; Puck JM
Clin Immunol; 2006 Jan; 118(1):59-65. PubMed ID: 16257267
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune lymphoproliferative syndrome.
Sneller MC; Dale JK; Straus SE
Curr Opin Rheumatol; 2003 Jul; 15(4):417-21. PubMed ID: 12819469
[TBL] [Abstract][Full Text] [Related]
15. A new disorder of lymphocyte apoptosis: combination of autoimmunity, infectious lymphadenopathy, double negative T cells, and impaired activation-induced cell death.
Hundt M; Posovszky C; Schmidt RE
Immunobiology; 2002 Dec; 206(5):514-8. PubMed ID: 12607726
[TBL] [Abstract][Full Text] [Related]
16. The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis.
Fleisher TA
Immunol Res; 2008; 40(1):87-92. PubMed ID: 18193364
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil as an alternate immunosuppressor for autoimmune lymphoproliferative syndrome.
Kossiva L; Theodoridou M; Mostrou G; Vrachnou E; Le Deist F; Rieux-Laucat F; Kanariou MG
J Pediatr Hematol Oncol; 2006 Dec; 28(12):824-6. PubMed ID: 17164652
[TBL] [Abstract][Full Text] [Related]
18. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.
Fisher GH; Rosenberg FJ; Straus SE; Dale JK; Middleton LA; Lin AY; Strober W; Lenardo MJ; Puck JM
Cell; 1995 Jun; 81(6):935-46. PubMed ID: 7540117
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune lymphoproliferative syndrome with somatic Fas mutations.
Holzelova E; Vonarbourg C; Stolzenberg MC; Arkwright PD; Selz F; Prieur AM; Blanche S; Bartunkova J; Vilmer E; Fischer A; Le Deist F; Rieux-Laucat F
N Engl J Med; 2004 Sep; 351(14):1409-18. PubMed ID: 15459302
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis.
Jackson CE; Puck JM
Curr Opin Pediatr; 1999 Dec; 11(6):521-7. PubMed ID: 10590910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
